Core Insights - Editas Medicine is transitioning to focus exclusively on in vivo CRISPR-edited medicines, driven by recent scientific advancements that have accelerated timelines for viability in this area [2][3] - The company has achieved significant pre-clinical proof of concept in multiple tissues, including a ~40% editing of the HBG1/2 promoter site in hematopoietic stem cells (HSCs) and high efficiency editing in the liver of non-human primates [3][4] - Editas plans to extend its cash runway into Q2 2027 through cost-saving measures, including a reduction of approximately 65% of its workforce [6][10] Scientific Progress - The company has successfully induced HbF expression in human red blood cells, with an average of 20% HbF expressing cells observed one month post-treatment in mice [3] - The proprietary targeted lipid nanoparticle (tLNP) formulation was utilized for effective delivery of gene editing machinery to HSCs [3] - High efficiency editing in the liver was achieved in collaboration with Genevant, with further data expected to be shared in Q1 2025 [4] Strategic Changes - Editas is discontinuing the development of reni-cel due to the inability to secure a commercial partner, and will focus on the RUBY and EdiTHAL trials for sickle cell disease and beta thalassemia [1][8] - The company is implementing a significant workforce reduction, which will include departures from the management team [6][7] - The transition to a fully in vivo company is aimed at expanding therapeutic possibilities and positioning Editas as a leader in the CRISPR gene editing field [2][5]

It has been about a month since the last earnings report for Editas Medicine (EDIT) . Shares have lost about 36.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Editas Q3 Loss Narrower Than Expected, Revenue ...

Editas Medicine, Inc. (NASDAQ:EDIT) 7th Annual Evercore HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Erick Lucera - Executive Vice President and Chief Financial Officer Cristi Barnett - Senior Vice President, Corporate Communications and Investor Relations Conference Call Participants Liisa Bayko - Evercore ISI Liisa Bayko Okay, welcome everyone. This is Evercore’s Healthcare Conference. I'm Liisa Bayko, one of this mid-cap analysts here at Evercore, and I've been covering Editas a ...

BofA Securities downgraded Editas Medicine Inc EDIT, citing few value-driving catalysts in the near term. In its third-quarter earnings release, Editas Medicine said it engaged an investment bank to lead the process of partnering or out-licensing reni-cel (renizgamglogene autogedtemcel, previously EDIT-301). The company is developing reni-cel for sickle cell disease and transfusion-dependent Beta Thalassemia. The company is on track to share additional clinical and patient-reported outcomes data from 28 pat ...

Editas Medicine, Inc. (NASDAQ:EDIT) Stifel 2024 Healthcare Conference November 19, 2024 1:50 PM ET Company Participants Erick Lucera - Chief Financial Officer Conference Call Participants Dae Gon Ha - Stifel Dae Gon Ha All right. Thanks, everyone, for joining us for the next half hour. My name is Dae Gon Ha, one of the biotech analysts at Stifel. So with me for the next half hour, we've got Editas Medicine. So from Editas, we have Erick Lucera, Chief Financial Officer and Christine [indiscernible] VP of IR. ...

Editas Medicine (EDIT) incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported a loss of 55 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $0.1 million in the reported quarter, down from $5.3 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. Th ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.32%. A quarter ago, it was expected that this genome editing company would post a loss of $0.69 per share when it actually produced a loss of $0.82, delivering a surprise of -18.84%.Over the last four quarters, the compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________ FORM 10-Q _______________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ________ Commission File Number 001-37687 ______________ ...

Clinical Development - Achieved in vivo preclinical proof of concept for hematopoietic stem and progenitor cell editing, demonstrating a 29% editing level in HSPCs after a single dose[3] - Induced fetal hemoglobin (HbF) expression in human red blood cells, with an average of 20% HbF expressing cells present one month post-treatment[3] - Reni-cel (renizgamglogene autogedtemcel) is on track to present clinical data at the ASH Annual Meeting on December 7-10, 2024, following the completion of enrollment for adolescent and adult cohorts in the RUBY trial[4] - Completed enrollment of the adult cohort in the EdiTHAL trial for transfusion-dependent beta thalassemia, with additional clinical data expected by year-end 2024[5] Financial Performance - Sold future license fees under the Cas9 license agreement to DRI Healthcare Trust for an upfront cash payment of $57 million, enhancing non-dilutive capital for pipeline development[6] - Ended Q3 2024 with approximately $265 million in cash, cash equivalents, and marketable securities, increasing to approximately $320 million post-receipt of DRI payment[6] Strategic Partnerships - Engaged Moelis & Company LLC to lead the global process for partnering or out-licensing reni-cel, aiming to reduce spending in 2025[6] - Focused on optimal capital use while advancing the in vivo pipeline and evaluating opportunities for reni-cel commercialization[2] Technology and Innovation - The proprietary targeted lipid nanoparticle (tLNP) formulation is key for extrahepatic tissue delivery, positioning the company for leadership in in vivo programmable gene editing[2] - The company aims to deliver transformative genomic medicines for serious diseases, leveraging CRISPR/Cas12a and Cas9 genome editing systems[8]

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on ...